News
ZTS
76.92
+2.08%
1.57
Zoetis (ZTS) Beats Stock Market Upswing: What Investors Need to Know
NASDAQ · 5h ago
Zoetis Price Target Cut to $85.00/Share From $99.00 by UBS
Dow Jones · 9h ago
Zoetis Is Maintained at Neutral by UBS
Dow Jones · 9h ago
UBS Maintains Neutral on Zoetis, Lowers Price Target to $85
Benzinga · 9h ago
Weekly Report: what happened at ZTS last week (0720-0724)?
Weekly Report · 18h ago
How Lenivia’s Long-Acting Canine OA Launch At Zoetis (ZTS) Has Changed Its Investment Story
Simply Wall St · 2d ago
Friday's ETF with Unusual Volume: FTXH
NASDAQ · 3d ago
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 3d ago
Zoetis (ZTS) Launches New Pet Pain Treatments As Valuation Questions Return
Simply Wall St · 3d ago
Why Dividend Investing Often Wins
Seeking Alpha · 3d ago
Zoetis: Sentiment Keeps Winning As Fundamentals Improve
Seeking Alpha · 3d ago
3 Healthcare Stocks with Competitive Advantages
Barchart · 4d ago
Zoetis Is Maintained at Overweight by Morgan Stanley
Dow Jones · 5d ago
Zoetis Price Target Cut to $99.00/Share From $115.00 by Morgan Stanley
Dow Jones · 5d ago
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $99
Benzinga · 5d ago
Zoetis price target lowered to $99 from $115 at Morgan Stanley
TipRanks · 5d ago
Zoetis launches Portela in Canada, the EU
TipRanks · 5d ago
Zoetis Commercially Rolls Out Portela In Canada, EU To Treat Pain Associated With Osteoarthritis
Benzinga · 5d ago
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 6d ago
ZTS Deadline: ZTS Investors with Loses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
PR Newswire · 07/20 20:15
More
Webull provides a variety of real-time ZTS stock news. You can receive the latest news about Zoetis Inc through multiple platforms. This information may help you make smarter investment decisions.
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).